Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Dermatophagoides Pteronyssinus
Brand Name
Standardized Mite Dermatophagoides Pteronyssinus
Generic Name
Dermatophagoides Pteronyssinus
Active Ingredient
Dermatophagoides PteronyssinusCategory
Standardized Insect Allergenic Extract [EPC]
Variants
3
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 30000 [AU]/mL | CONCENTRATE | INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS | 22840-0039 |
| 10000 [AU]/mL | CONCENTRATE | INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS | 22840-0036 |
| 5000 [AU]/mL | CONCENTRATE | INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Standardized Mite Dermatophagoides Pteronyssinus, you must consult a qualified healthcare professional.
| 22840-0035 |
Detailed information about Standardized Mite Dermatophagoides Pteronyssinus
Dermatophagoides Pteronyssinus is a standardized allergenic extract used in the diagnosis and treatment of house dust mite-induced allergic rhinitis and asthma. It belongs to the class of allergenic extracts designed to induce immune tolerance through immunotherapy.
For Sublingual Immunotherapy (SLIT), the standard adult dose is typically one tablet (e.g., 12 SQ-HDM) administered once daily. Treatment is often initiated at any time of the year, as house dust mites are perennial allergens.
For Subcutaneous Immunotherapy (SCIT), the dosage is highly individualized and follows a two-phase approach:
The use of Dermatophagoides Pteronyssinus extracts in children depends on the specific product and formulation:
No specific dosage adjustments are required for patients with renal impairment, as the proteins are not cleared via the kidneys in a manner that would lead to systemic accumulation.
No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins occurs via local cellular proteolytic pathways rather than the cytochrome P450 system.
Clinical trials for products like Odactra included patients up to age 65. Data for patients over 65 are limited. Healthcare providers should assess the cardiovascular status of elderly patients, as they may be less likely to tolerate the epinephrine required to treat a potential systemic reaction.
If a dose of the sublingual tablet is missed, skip the missed dose and resume the regular schedule the next day. Do not double the dose. If more than one dose is missed, contact your healthcare provider before restarting, as a dose adjustment may be necessary to prevent reactions. For missed injections, the schedule may need to be 'stepped back' to a lower dose depending on the length of the delay.
An overdose of allergenic extract increases the risk of severe local and systemic allergic reactions. Symptoms may include severe swelling of the tongue or throat, difficulty breathing, or hives. In the event of a suspected overdose or severe reaction, seek emergency medical attention immediately. If prescribed, an epinephrine autoinjector should be used as directed by your physician.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop treatment without medical guidance, as this can affect the efficacy and safety of the immunotherapy.
Side effects from Dermatophagoides Pteronyssinus extracts are most common during the first few weeks of treatment as the immune system begins to adapt. For sublingual administration, these include:
Dermatophagoides Pteronyssinus immunotherapy is a potent biological treatment that requires careful patient selection. It is not a 'rescue' medication and will not provide immediate relief during an acute allergy attack or asthma flare-up. Patients must be committed to a long-term treatment plan, often lasting several years, to achieve clinical benefit.
As noted in the side effects section, the FDA has mandated a Black Box Warning for sublingual house dust mite extracts. The primary concern is Anaphylaxis. Because this treatment is administered at home (after the first dose), patients must be able to recognize the signs of a systemic reaction and be physically and mentally capable of administering an epinephrine injection if necessary.
While there are few absolute drug-drug contraindications, the following combinations are generally avoided due to safety concerns regarding the management of potential reactions:
Dermatophagoides Pteronyssinus extracts must NEVER be used in the following circumstances:
It is not known whether Dermatophagoides Pteronyssinus allergenic proteins are excreted in human milk. However, since these are large proteins that are processed locally in the oral mucosa or injection site, systemic absorption is minimal. Most experts consider it safe to continue immunotherapy while breastfeeding, as the proteins would likely be digested in the infant's stomach even if small amounts were present in the milk.
Dermatophagoides Pteronyssinus extract acts as an immunobiological modifier. The extract contains major allergens, specifically Der p 1 (a cysteine protease) and Der p 2 (a lipid-binding protein). When these proteins are presented to the immune system in a controlled, repetitive manner, they interact with dendritic cells and T-lymphocytes. This leads to the induction of Peripheral Tolerance. The key molecular event is the shift from a pro-allergic Th2 cytokine profile (IL-4, IL-5, IL-13) to a regulatory profile (IL-10, TGF-β), which suppresses IgE production and promotes the synthesis of protective IgG4 antibodies.
The pharmacodynamic effect is measured by a decrease in the 'Early Phase Response' (immediate histamine release) and the 'Late Phase Response' (tissue eosinophilia and inflammation). Clinical onset is slow; it typically takes 8 to 14 weeks of daily treatment to observe a noticeable reduction in allergy symptoms. The duration of effect can be long-lasting, with studies suggesting that a completed 3-year course can provide benefit for several years after treatment is discontinued.
Common questions about Standardized Mite Dermatophagoides Pteronyssinus
Dermatophagoides Pteronyssinus extract is used for the treatment and diagnosis of allergies caused by the European house dust mite. It is primarily indicated for patients with allergic rhinitis (hay fever) and allergic conjunctivitis who have not responded well enough to standard allergy medications. By exposing the immune system to small, controlled amounts of the mite proteins, it helps the body develop tolerance. This can lead to a significant reduction in symptoms like sneezing, runny nose, and itchy eyes. It is also used by allergists in skin prick tests to confirm if a patient is actually allergic to dust mites.
The most common side effects, especially with sublingual (under-the-tongue) tablets, include itching or tingling in the mouth, throat irritation, and mild swelling of the lips or tongue. These symptoms usually occur shortly after taking the dose and often go away within an hour. Some patients may also experience ear itching or a change in taste. These local reactions are most frequent during the first few weeks of treatment and typically decrease over time. If the swelling becomes severe or causes difficulty swallowing, you should contact your doctor immediately.
There is no known direct chemical interaction between alcohol and Dermatophagoides Pteronyssinus extracts. However, it is generally advised to avoid drinking alcohol shortly before or after taking your dose, as alcohol can cause the blood vessels in the mouth to dilate, which might change how the allergen is absorbed. Furthermore, alcohol can sometimes worsen allergy symptoms or make it harder for you to notice the early signs of a serious allergic reaction. Being alert and sober is important for safety, especially during the initial phases of immunotherapy. Always follow the specific advice provided by your healthcare professional regarding lifestyle choices during treatment.
Dermatophagoides Pteronyssinus is generally not started during pregnancy because of the risk of a severe allergic reaction (anaphylaxis), which could harm the developing fetus by reducing oxygen supply. However, if a woman is already on a stable maintenance dose and tolerating it well before becoming pregnant, many doctors allow the treatment to continue. The decision is based on a careful risk-benefit analysis between the mother and her allergist. There is no evidence that the extract itself causes birth defects. If you become pregnant while on this medication, notify your doctor immediately to discuss the safest course of action.
Immunotherapy is not a fast-acting treatment and requires patience. Most patients begin to see a reduction in their allergy symptoms after about 8 to 14 weeks of consistent daily use. The maximum benefit is often not reached until the patient has been on the medication for at least 6 to 12 months. Doctors typically recommend continuing the treatment for 3 to 5 years to ensure that the immune system remains desensitized even after the medication is stopped. If you do not see any improvement after 6 months, your doctor may re-evaluate whether this specific treatment is right for you.
While stopping Dermatophagoides Pteronyssinus suddenly does not cause dangerous withdrawal symptoms like some other drugs, it can significantly interfere with the success of your allergy treatment. If you stop the medication before the recommended 3-to-5-year course, your allergy symptoms are likely to return over time. If you miss several doses due to illness or travel, you should not simply restart at the same dose without consulting your doctor. A break in treatment can make your immune system more sensitive, increasing the risk of a reaction when you resume. Always talk to your allergist before making changes to your treatment schedule.
If you miss a single dose of a sublingual tablet, skip that dose and take your next scheduled dose the following day. Do not take two doses at once to make up for the missed one. If you miss more than one or two days of treatment, contact your healthcare provider for guidance. For those receiving injections (SCIT), a missed appointment may require the doctor to lower your next dose slightly to ensure safety before building back up. Consistency is key to 'training' your immune system, so try to take your medication at the same time each day.
There is no clinical evidence to suggest that Dermatophagoides Pteronyssinus extracts cause weight gain. The medication consists of proteins that act locally on the immune system and does not affect the body's metabolism, appetite, or fat storage. Unlike systemic corticosteroids (which are sometimes used for allergies and can cause weight gain), allergenic extracts work through a completely different biological pathway. If you experience unexpected weight changes while on this medication, they are likely due to other factors and should be discussed with your primary care physician.
Most common medications, such as vitamins, birth control, and standard allergy pills, can be taken with Dermatophagoides Pteronyssinus. However, certain drugs like beta-blockers and ACE inhibitors (used for blood pressure) can make the treatment more dangerous because they interfere with how the body responds to emergency treatment for an allergic reaction. You should also be cautious if you are taking other forms of immunotherapy simultaneously. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are using to prevent potentially serious interactions.
Dermatophagoides Pteronyssinus is a biological product rather than a simple chemical drug, so it does not have a 'generic' version in the traditional sense. However, there are multiple manufacturers that produce standardized and non-standardized extracts of this mite. For sublingual tablets, there are specific brand-name products like Odactra that have been rigorously tested for consistency. While different brands of extracts exist for injections, they are not always interchangeable because their concentrations and units of measurement (such as BAU vs. PNU) can vary. Your doctor will prescribe a specific product that is appropriate for your treatment plan.
Other drugs with the same active ingredient (Dermatophagoides Pteronyssinus)
> Warning: Stop taking Dermatophagoides Pteronyssinus and call your doctor or emergency services immediately if you experience any of the following symptoms of Anaphylaxis:
When used correctly under medical supervision, Dermatophagoides Pteronyssinus extracts do not typically cause long-term organ toxicity. The primary long-term consideration is the development of Eosinophilic Esophagitis. Patients who develop persistent heartburn, difficulty swallowing, or food getting stuck in the throat should be evaluated by a specialist. Most patients find that the local side effects (mouth itching) diminish significantly after the first 1–3 months of daily use.
Sublingual products containing Dermatophagoides Pteronyssinus (such as Odactra) carry an FDA Black Box Warning regarding the risk of severe allergic reactions.
Report any unusual symptoms or side effects to your healthcare provider to ensure your treatment plan remains safe and effective.
Dermatophagoides Pteronyssinus extracts generally do not cause drowsiness or cognitive impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until cleared by a medical professional.
There is no direct chemical interaction between alcohol and Dermatophagoides Pteronyssinus. However, alcohol consumption can cause vasodilation and may theoretically increase the speed of allergen absorption in the mouth. It is also important to remain sober so that any potential allergic symptoms can be accurately identified and managed.
If treatment is stopped for more than a few days, do not resume without consulting your doctor. A 're-escalation' of the dose may be required. Unlike many medications, there is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the allergy symptoms will likely return if the course of immunotherapy was not completed (usually 3–5 years).
> Important: Discuss all your medical conditions, especially respiratory or heart issues, with your healthcare provider before starting Dermatophagoides Pteronyssinus.
There are no well-documented interactions between Dermatophagoides Pteronyssinus and common herbal supplements like St. John's Wort or Ginkgo Biloba. However, supplements that have potent anti-inflammatory effects (like high-dose Curcumin or Boswellia) should be disclosed to your doctor, as they may theoretically influence the immune modulation process.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart conditions.
Conditions requiring a careful risk-benefit analysis by a specialist:
Patients allergic to Dermatophagoides pteronyssinus often show cross-reactivity with Dermatophagoides farinae (the American house dust mite) because they share similar protein structures. Many immunotherapy products contain a 50/50 mix of both species to provide broad protection. There is also a known cross-sensitivity between house dust mites and certain crustaceans (like shrimp or lobster) due to a shared protein called tropomyosin. Patients with severe shellfish allergies should inform their doctor, although they can usually still safely receive dust mite immunotherapy.
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Dermatophagoides Pteronyssinus.
Clinical trials included a limited number of patients aged 65 and older. The primary concern in the elderly is the presence of comorbid conditions (like heart disease) that would make an allergic reaction more dangerous. Pharmacokinetic changes associated with age (reduced kidney or liver function) do not significantly affect the use of this biological product.
No dosage adjustment is required. The clearance of the active allergenic proteins does not depend on renal function. However, patients with severe renal disease should be monitored for their overall ability to handle systemic stress.
No dosage adjustment is required. The liver's cytochrome P450 system is not involved in the processing of these allergenic proteins.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying organ dysfunction.
| Parameter | Value |
|---|---|
| Bioavailability | Low (systemically); High (mucosal capture) |
| Protein Binding | N/A (processed by immune cells) |
| Half-life | N/A (biological degradation) |
| Tmax | Local capture within minutes |
| Metabolism | Proteolytic degradation in lysosomes |
| Excretion | Not renally excreted as intact protein |
Dermatophagoides Pteronyssinus is classified as a Standardized Allergenic Extract. It belongs to the broader category of Antigen-Specific Immunotherapy. Related medications include extracts for Dermatophagoides farinae, Timothy grass pollen (Phleum pratense), and Ragweed pollen (Ambrosia artemisiifolia).